Merck is still running the phase 3 KEYLYNK-012 study for the Keytruda-Lynparza combo in stage 3 NSCLC. A Merck spokesperson confirmed to Fierce Pharma two weeks ago that the KEYLYNK-012 trial ...
The National Collegiate Athletic Association (NCAA) Division III membership committee approved Penn State Brandywine's application for provisional membership beginning Sept. 1. During the three-year ...